Koers Ventrus Biosciences Inc Nasdaq
Aandelen
US9228221019
Farmaceutische producten
slotkoers
Andere beurzen
|
||
- USD | - |
Omzet 2024 * | 24,2 mln. 22,28 mln. | Omzet 2025 * | 14,52 mln. 13,37 mln. | Marktkapitalisatie | 83,14 mln. 76,52 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -52 mln. -47,86 mln. | Nettowinst (verlies) 2025 * | -54 mln. -49,7 mln. | EV/omzet 2024 * | 3,44 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 5,73 x |
K/w-verhouding 2024 * |
-1,59
x | K/w-verhouding 2025 * |
-1,57
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 66,94% |
Recentste transcriptie over Ventrus Biosciences Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Jason Okazaki
CEO | Chief Executive Officer | 48 | 30-03-20 |
Anuj Gaggar
CTO | Chief Tech/Sci/R&D Officer | 46 | 08/11 |
William Delaney
CTO | Chief Tech/Sci/R&D Officer | 52 | 01-06-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Susan Mahony
BRD | Director/Board Member | 59 | 14-12-17 |
Gina Consylman
BRD | Director/Board Member | 52 | 20-10-20 |
William Ringo
CHM | Chairman | 78 | 01-07-14 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+16,34% | 79,03 mld. | |
+8,65% | 8,78 mld. | |
-16,33% | 4,83 mld. | |
+51,22% | 4,65 mld. | |
+2,18% | 3,89 mld. | |
+20,51% | 2,34 mld. | |
-26,79% | 2,18 mld. | |
+15,12% | 2,11 mld. | |
-36,56% | 2 mld. |
- Beurs
- Aandelen
- Koers ASMB
- Koers